Collegium Pharmaceutical (COLL) announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150M in common stock through December 31, 2026. This program replaces a previous $150M share repurchase program authorized in January 2024 which expired on June 30, 2025, and had $65M remaining under the program.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical Approves 2025 Equity Incentive Plan
- Collegium Pharmaceutical announces $25M accelerated share repurchase program
- Collegium Pharmaceutical Announces Share Repurchase Agreement
- Collegium Pharmaceutical’s Earnings Call Highlights Growth and Strategic Initiatives
- Collegium Pharmaceutical price target raised to $37 from $36 at Piper Sandler